Why the study?
To examine the influence of class III antiarrhythmic drugs Refralon, Sotalol, and E-4031 on left atrial and pulmonary vein myocardium under conditions of hypoxia and acidification.
Do potassium channel blockers (Refralon, Sotalol, E-4031) improve effective refractory period and prevent premature heart beats in rat atrial and pulmonary vein myocardium under hypoxia and acidification?
Do potassium channel blockers (Refralon, Sotalol, E-4031) improve effective refractory period and prevent premature heart beats in rat atrial and pulmonary vein myocardium under hypoxia and acidification?
Refralon increases effective refractory period and prevents premature heart beats under hypoxia in rat atrial tissue, indicating potential utility for atrial fibrillation in hypoxic conditions.
Answers are grounded in this paper and cite their sources.
Refralon may preserve refractoriness under hypoxia; leaves open differential class III effects in ischemic atrial tissue.
Class III antiarrhythmic drugs are most commonly used for atrial fibrillation. These drugs block potassium currents responsible for restoration of resting potential and increase action potential duration (APD) and excitation wavelength. Objective. To study the influence of Refralon, Sotalol and E-4031 on myocardium of the left atrium and pulmonary vein orifices under hypoxia and acidification (pH=6.6). Material and methods. We analyzed the effects of Refralon, Sotalol and E-4031 on the left atrium and distal part of pulmonary vein in rats using multichannel microelectrode technology. Results. Hypoxia insignificantly decreased effective refractory period in the atrium, pulmonary vein orifices and distal part of pulmonary vein. However, addition of Sotalol under hypoxia significantly reduced effective refractory period in the atrium, pulmonary vein orifices and distal part of pulmonary vein (77±4%, 78±5% and 76±3% of control values, respectively, p<0.05). Addition of E-4031 under hypoxia did not significantly change effective refractory period. At the same time, Refralon significantly increased effective refractory period under hypoxia (125±3%, 125±4%, 148±5% of control values in the atrium, pulmonary vein orifices and distal part of pulmonary vein, respectively, p<0.05). Acidification significantly reduced effective refractory period in the atrium, pulmonary vein orifices and distal part of pulmonary vein (76±3%, 75±4%, 74±5% of control values, respectively, p<0.05). Addition of Sotalol did not lead to recovery of effective refractory period (84±5%, 81±6%, 78±9% of control values in the atrium, pulmonary vein orifices and distal part of pulmonary vein, respectively, p<0.05). Refralon and E-4031 restored effective refractory period up to control values. In the control, the probability of premature heart beat was 42% (15/36). Under hypoxia, this value was the same (39%, 7/18). The probability was 61% (11/18) at pH=6.6. Addition of Sotalol under hypoxia increased the likelihood of premature heart beat to 80% (4/5), E-4031 did not significantly affect the likelihood of premature heart beat (40%, 2/5). No premature heart beats were observed under the action of Refralon (0/8). At pH=6.6 and addition of Sotalol, the probability of premature heart beat reached 83% (5/6). E-4031 and Refralon did not significantly affect the probability of premature heart beats (50%, 3/6). Conclusion. Ikr current blockers (Refralon, E-4031) contribute to effective refractory period recovery and prevention of premature heart beats under acidification, except for Sotalol. Refralon increased effective refractory period under hypoxia in contrast to E-4031 and Sotalol, as well as reduced the likelihood of premature heart beats. Refralon also increased functional refractory period under hypoxia that can indicate its efficacy for correction of atrial fibrillation and atrial flatter under hypoxia.
No takes yet. Share an insight, caveat, or question.
Yu. V. Egorov (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: